DV
Dividend Vision

INDV — Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. (INDV)

Total return is 281.1% over the past 11.6 years, 69.2 points behind SPY at 350.3%. Its deepest 1-year drawdown was 21.4%.

Indivior Pharmaceuticals develops, manufactures, and sells buprenorphine-based prescription medications for treating opioid use disorder, with marketed products including SUBLOCADE monthly injections and SUBOXONE films and tablets, along with pipeline candidates in clinical development. The company does not currently distribute dividends. Indivior Pharmaceuticals appeals primarily to investors seeking exposure to the pharmaceutical and healthcare sectors, particularly those focused on addiction medicine and substance use disorder treatments.

INDV key facts

Asset type
Stock
Asset class
Equity
Inception date
12/29/2014
Last close
$39.01
Market cap
$4,603,712,000
Average volume
988400.0
Ex-dividend date
06/16/2016
Payment date
07/29/2016
Beta
1.136
Payout ratio
0.0
P/E ratio
13.9821
Forward P/E
10.4493
EPS
$2.79